



Balfour Capital Group Johnson & Johnson

Johnson & Johnson (J&J) is a global healthcare leader specializing in pharmaceuticals and medical technologies. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J operates in over 60 countries with a workforce of approximately 138,100 employees. In 2023, the company spun off its consumer health division into a separate entity named Kenvue, allowing J&J to focus exclusively on innovative medicine and MedTech solutions.

1. Top 5 Competitors

J&J competes with several major players in the healthcare sector:

1. Pfizer Inc.
2. Merck & Co., Inc.
3. Novartis AG
4. AbbVie Inc.
5. Roche Holding AG

These companies are prominent in pharmaceuticals and biotechnology, offering a range of products that compete directly with J&J's offerings.

2. Largest Institutional Shareholders

As of December 2024, institutional investors hold approximately 73.57% of J&J's outstanding shares. The top institutional shareholders include:

- The Vanguard Group – 9.67%
- BlackRock Inc. – 8.36%
- State Street Corporation – 5.58%
- Geode Capital Management – 2.40%
- Morgan Stanley – 1.82%
- JPMorgan Chase & Co. – 1.61%
- State Farm – 1.32%
- Northern Trust – 1.28%
- Norges Bank – 1.26%
- Wellington Management Group – 1.01%



Balfour Capital Group Johnson & Johnson

3. Management Team

J&J's executive leadership is comprised of seasoned professionals:

- Joaquin Duato – Chairman and Chief Executive Officer
- Joseph J. Wolk – Executive Vice President, Chief Financial Officer
- Peter Fasolo – Executive Vice President, Chief Human Resources Officer
- Vanessa Broadhurst – Executive Vice President, Global Corporate Affairs
- Liz Forminard – Executive Vice President, General Counsel
- Kristen Mulholland – Executive Vice President, Chief Compliance Officer
- John C. Reed, M.D., Ph.D. – Executive Vice President, Innovative Medicine, R&D
- Tim Schmid – Executive Vice President, Worldwide Chairman, MedTech
- James Swanson – Executive Vice President, Chief Information Officer

4. Revenue

In the fiscal year 2024, J&J reported:

- Revenue: \$88.82 billion (a 4.3% increase from 2023)

Net Income: \$14.07 billion

For the first quarter of 2025, the company reported:

- Revenue: \$21.89 billion (a 2.4% year-over-year increase)
- Adjusted EPS: \$2.77

J&J has raised its full-year 2025 revenue forecast to between \$91.0 billion and \$91.8 billion.

5. Institutions with Buy Recommendations:

Analyst sentiment towards J&J remains positive:

- Average Rating: Moderate Buy (3.87 out of 5)
- Average 12-Month Price Target: \$170.8

Additionally, AI-driven analysis platforms like Danelfin have assigned J&J a high AI Score of 9/10, indicating a strong probability of outperforming the market in the near term.



Balfour Capital Group Johnson & Johnson

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, insider trading activity at J&J has been relatively modest:

- Purchases: 509,674 shares across 21 transactions
- Sales: 20,417 shares across 3 transactions
- Net Shares Purchased: 489,257 shares across 24 transaction,

Notably, in the past 90 days, there have been two insider sales:

- Robert J. Decker, VP Corporate Controller, sold 6,999 shares valued at approximately \$1.16 million on February 25, 2025.
- Timothy Schmid, EVP of MedTech, sold 403 shares for approximately \$62,928 on February 18, 2025.

